The key efficacy endpoint was transform from baseline MADRS score. This limited-phrase research found that, in comparison with intranasal placebo furthermore oral antidepressant, intranasal esketamine along side an oral antidepressant appreciably improved depressive symptoms after 4 months by a sugg